CAR-T Construction Service

  • Check with publisher
  • Published date: April 28, 2018
    • Shirley, New York, United States

As a CAR technology leader, Creative Biolabs has established an unparalleled platform for Chimeric Antigen Receptor (CAR) modified T cell construction, which can satisfy various needs for developing treatments of multiply cancers in preclinical studies and researches.

Result 0 votes
Jerry Carter
1 votes

Useful information

  • Avoid scams by acting locally or paying with PayPal
  • Never pay with Western Union, Moneygram or other anonymous payment services
  • Don't buy or sell outside of your country. Don't accept cashier cheques from outside your country
  • This site is never involved in any transaction, and does not handle payments, shipping, guarantee transactions, provide escrow services, or offer "buyer protection" or "seller certification"

Related listings

  • Anti-ROS-CII Antibody-Cytokine Fusion Protein, scFv (1-11E)-IL10

    Anti-ROS-CII Antibody-Cytokine Fusion Protein, scFv (1-11E)-IL10

    Drug Development Shirley (New York) June 29, 2020 1.00 Dollar US$

    This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-ROS-CII scFv to IL10. It was expressed in CHO and purified with affinity chromatography. The immunocytokine retains the ability to bind the ROS-CII as well as the biolo...

  • 5-Bromoindole


    Drug Development Shirley (New York) February 13, 2020 Check with publisher

    5-Bromoindole is a GSK-3 inhibitor.

  • FM19G11


    Drug Development Shirley (New York) February 13, 2020 Check with publisher

    FM19G11 is a hypoxia inducible factors α (HIFα) inhibitor. It has been reported to inhibit transcriptional activity of pluripotency markers (Sox2 and Oct4) in rodent and human stem cells under hypoxic conditions.